About: Peramivir for Influenza A and B Viral Infections: A Pharmacokinetic Case Series

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Peramivir for Influenza A and B Viral Infections: A Pharmacokinetic Case Series Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Peramivir for Influenza A and B Viral Infections: A Pharmacokinetic Case Series
Creator	Chopra, Arun Cies, Jeffrey Enache, Adela Ii, Wayne
Source	PMC
abstract	OBJECTIVE: To describe the peramivir (PRV) pharmacokinetics in critically ill children treated for influenza A or B viral infections. DESIGN: Retrospective electronic medical record review of prospectively collected data from critically ill children receiving peramivir for influenza A or B viral infections in the pediatric intensive care unit (PICU). SETTING: A 189‐bed, freestanding children's tertiary care teaching hospital in Philadelphia, PA. PATIENTS: Critically ill children admitted to the PICU who were infected with influenza between January 1, 2016 and March 31, 2018. INTERVENTIONS: None. RESULTS: Eleven patients, two females (18%) and nine males (82%), accounted for 24 peramivir samples for therapeutic drug management. The median age was 5 years (interquartile range 1.5–6.5 yrs) with a median weight of 16.4 kg (interquartile range 14–24 kg). Ten (91%) patients demonstrated a larger volume of distribution, 11 (100%) patients demonstrated an increase in clearance, and 11 (100%) patients demonstrated a shorter half‐life estimate as compared with the package insert and previous pediatric trial data for peramivir. Eight (73%) patients tested positive for a strain of influenza A and 3 (27%) patients tested positive for influenza B; 4 of 11 (36%) patients tested positive for multiple viruses. All patients had adjustments made to their dosing interval to a more frequent interval. Ten (91%) patients were adjusted to an every‐12‐hour regimen and 1 (9%) patient was adjusted to an every‐8‐hour regimen. No adverse events were associated with peramivir treatment. CONCLUSION: The pharmacokinetics of PRV demonstrated in this PICU cohort differs in comparison to healthy pediatric and adult patients, and alterations to dosing regimens may be needed in PICU patients to achieve pharmacodynamic exposures. Additional investigations in the PICU population are needed to confirm these findings.
has issue date	2019-10-04(xsd:dateTime)
bibo:doi	10.1002/phar.2330
bibo:pmid	31514223
has license	no-cc
sha1sum (hex)	b2503aa9036bf546348aace94f0375026ae5f379
schema:url	https://doi.org/10.1002/phar.2330
resource representing a document's title	Peramivir for Influenza A and B Viral Infections: A Pharmacokinetic Case Series
has PubMed Central identifier	PMC7167779
has PubMed identifier	31514223
schema:publication	Pharmacotherapy
resource representing a document's body	covid:b2503aa9036bf546348aace94f0375026ae5f379#body_text
is schema:about of	named entity 'Viral Infections' named entity '8 days' named entity 'extracorporeal therapy' named entity 'PRV' named entity 'emergency use authorization' named entity 'virus' named entity 'PRV' named entity 'H1N1' named entity 'pharmacodynamic' named entity 'Peramivir' named entity 'PRV' named entity 'pediatric patients' named entity 'pharmacokinetic' named entity 'polymerase chain reaction' named entity 'concentration measurements' named entity 'Peramivir' named entity 'liquid chromatography-tandem mass spectrometry' named entity 'pharmacokinetic' named entity 'FDA' named entity 'PRV' named entity 'blood samples' named entity 'creatinine clearance' named entity 'correlation coefficient' named entity 'TDM' named entity 'pharmacokinetic' named entity 'United States' named entity 'antimicrobial stewardship' named entity 'pharmacokinetic' named entity 'influenza' named entity 'Half-life' named entity 'RT-PCR' named entity 'package insert' named entity 'pharmacokinetic' named entity 'pediatric patients' named entity 'influenza' named entity 'PRV' named entity 'definitive therapy' named entity 'therapeutic drug' named entity 'uncontrolled study' named entity 'antimicrobial agents' named entity 'antiviral activity' named entity 'pharmacokinetic' named entity 'U.S.A.' named entity 'critical illness' named entity 'pharmacokinetic' named entity 'PRV' named entity 'life-span' named entity 'blood samples' named entity 'volume of distribution' named entity 'antimicrobial resistance' named entity 'chronic renal failure' named entity 'protein binding' named entity 'Rapivab' named entity 'drug development' named entity 'half-life' named entity 'critically ill patients' named entity 'area under the curve' named entity 'microorganisms' named entity 'case series' named entity 'infectious diseases' named entity 'PICU' named entity 'PICU' named entity 'antibiotic' named entity '2009 pandemic H1N1 influenza' named entity 'adverse events' named entity 'pediatric' named entity 'surrogate marker' named entity 'pharmacokinetic' named entity 'polymerase chain reaction' named entity 'pediatric patients' named entity 'IDSA' named entity 'PICU' named entity 'PCR' named entity 'anti-infective' named entity 'epithelial lining' named entity 'critically ill' named entity 'Demographic' named entity 'oseltamivir'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software